Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors
This genomic model can become a clinically useful ancillary tool that is highly specific for differentiating melanomas from nevi.
Authors
- James S. Wilmott (ORCID: https://orcid.org/0000-0002-6750-5244)
- Andrew J. Colebatch (ORCID: https://orcid.org/0000-0002-7610-3984)
- Alison J. Potter (ORCID: https://orcid.org/0000-0001-5493-6021)
- Jordan W. Conway (ORCID: https://orcid.org/0000-0003-1161-9119)
- Serigne Lo (ORCID: https://orcid.org/0000-0001-5092-5544)
- Ismael A. Vergara (ORCID: https://orcid.org/0000-0002-2960-2967)
- Nigel G. Maher (ORCID: https://orcid.org/0000-0002-8140-2719)
- Elizabeth C. Paver (ORCID: https://orcid.org/0000-0001-6790-3501)
- Georgina Venetia Long (ORCID: https://orcid.org/0000-0001-8894-3545)
- Richard A. Scolyer (ORCID: https://orcid.org/0000-0002-8991-0013)
Institutions
- The University of Sydney (AU)
- Royal Prince Alfred Hospital (AU)
- Royal North Shore Hospital (AU)
- Canberra Hospital (AU)
- Melanoma Institute Australia (AU)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-06-30
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-1902
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00